| __timestamp | Intra-Cellular Therapies, Inc. | Mesoblast Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 21226345 | 55305000 |
| Thursday, January 1, 2015 | 87718074 | 77593000 |
| Friday, January 1, 2016 | 93831530 | 50013000 |
| Sunday, January 1, 2017 | 79419009 | 58914000 |
| Monday, January 1, 2018 | 132166913 | 65927000 |
| Tuesday, January 1, 2019 | 89124838 | 59815000 |
| Wednesday, January 1, 2020 | 65782137 | 56188000 |
| Friday, January 1, 2021 | 88845513 | 53012000 |
| Saturday, January 1, 2022 | 134715000 | 32815000 |
| Sunday, January 1, 2023 | 180142000 | 27189000 |
| Monday, January 1, 2024 | 25353000 |
Cracking the code
In the competitive world of biotechnology, innovation is the lifeblood of success. Intra-Cellular Therapies, Inc. and Mesoblast Limited are two companies that have been at the forefront of this race. Over the past decade, Intra-Cellular Therapies has consistently outpaced Mesoblast in research and development (R&D) spending. By 2023, Intra-Cellular Therapies had increased its R&D investment by over 750% since 2014, reaching a peak of $180 million. In contrast, Mesoblast's R&D expenses have seen a more modest increase, peaking at $77 million in 2015 and gradually declining to $27 million by 2023. This disparity highlights Intra-Cellular Therapies' aggressive push towards innovation, while Mesoblast appears to be adopting a more conservative approach. As the biotech industry continues to evolve, these investment strategies could significantly impact each company's future growth and market position.
Sanofi or Intra-Cellular Therapies, Inc.: Who Invests More in Innovation?
Research and Development Investment: Incyte Corporation vs Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. vs Insmed Incorporated: Strategic Focus on R&D Spending
Research and Development Investment: Intra-Cellular Therapies, Inc. vs Ionis Pharmaceuticals, Inc.
R&D Insights: How Intra-Cellular Therapies, Inc. and Alpine Immune Sciences, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Intra-Cellular Therapies, Inc. and CymaBay Therapeutics, Inc.
Comparing Innovation Spending: Intra-Cellular Therapies, Inc. and HUTCHMED (China) Limited
Research and Development Investment: Dr. Reddy's Laboratories Limited vs Mesoblast Limited
Analyzing R&D Budgets: ADMA Biologics, Inc. vs Mesoblast Limited
Research and Development Expenses Breakdown: CRISPR Therapeutics AG vs Mesoblast Limited
Research and Development: Comparing Key Metrics for Mesoblast Limited and Novavax, Inc.
R&D Spending Showdown: Mesoblast Limited vs MiMedx Group, Inc.